Jaguar’s name is now Jaguar Health!

On Monday, July 31, the merger of Jaguar Animal Health and Napo Pharmaceuticals became effective. Napo focuses on the development and commercialization of proprietary gastrointestinal pharmaceuticals for the global human marketplace from sustainably derived plants used traditionally in rainforest areas. As a result of the merger, Jaguar’s name is now Jaguar Health, Inc., and Napo is a wholly-owned subsidiary of Jaguar, focused on the continuing commercialization of its Mytesi® (crofelemer) product, which is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

For noninfectious diarrhea in adults living with HIV/AIDS who are on ART*

Mytesi® is the ONLY FDA-approved diarrhea treatment that's been studied specifically in adults with HIV/AIDS1

Important Safety Information: MYTESI® is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). MYTESI® is not indicated for the treatment of infectious diarrhea. Read More...

Serving a Broad Range of Species

Our animal health products will serve companion animals, horses and livestock with prescription and non-prescription products globally.

Buy Neonorm Foal Buy Neonorm Calf

Access to Powerful, Natural Compounds

Jaguar and Napo maintain a proprietary library of more than 2,300 medicinal plants.

Buy Neonorm Foal Buy Neonorm Calf

Committed to Human and Animal Health

We are focused on the development & commercialization of human and animal health solutions that are naturally derived & sustainably harvested.

Buy Neonorm Foal Buy Neonorm Calf

New Anti-Diarrheal Product for Foals
Is your current foal diarrhea product supported by clinical evidence? (We suspect not)

Buy Neonorm Foal

Naturally derived health solutions for humans and animals around the world

About Us

In conjunction with Napo Pharmaceuticals, our wholly-owned subsidiary, Jaguar Health is focused on developing and commercializing a range of first-in-class gastrointestinal prescription products for humans and animals, as well as non-prescription gastrointestinal products for animals.

Mission

We are committed to identifying human and animal health market opportunities where we can develop targeted products that leverage our broad intellectual property portfolio, deep pipeline and extensive botanical library.

News

November 28, 2017: Intestinal Lymphoma in Horses
READ MORE
November 22, 2017: Our Commitment to Social Responsibility & Sustainability
READ MORE
November 21, 2017: The Golden Retriever Lifetime Study
READ MORE

1 Orange Book, www.accessdata.fda.gov/scripts/cder/ob/, accessed October 2016

*Indication
MYTESI® is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART).

Important Safety Information about MYTESI®
MYTESI® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting MYTESI®.

If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

Click to Read Full Prescribing Information